GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Concord Drugs Ltd (BOM:538965) » Definitions » Pre-Tax Income

Concord Drugs (BOM:538965) Pre-Tax Income : ₹13.2 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Concord Drugs Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Concord Drugs's pretax income for the three months ended in Dec. 2023 was ₹-2.6 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was ₹13.2 Mil. Concord Drugs's pretax margin was -2.01%.

During the past 10 years, Concord Drugs's highest Pretax Margin was 8.36%. The lowest was 0.89%. And the median was 1.83%.


Concord Drugs Pre-Tax Income Historical Data

The historical data trend for Concord Drugs's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Drugs Pre-Tax Income Chart

Concord Drugs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.40 4.57 42.92 22.48 12.49

Concord Drugs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.16 1.41 6.35 7.98 -2.57

Competitive Comparison of Concord Drugs's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Drugs's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Concord Drugs's Pre-Tax Income falls into.



Concord Drugs Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Concord Drugs's Pretax Income for the fiscal year that ended in Mar. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=30.555+0+-17.283+0.06+-0.843
=12.5

Concord Drugs's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=2.398+0+-4.967+0+-4.4408920985006E-16
=-2.6

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹13.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Concord Drugs  (BOM:538965) Pre-Tax Income Explanation

Concord Drugs's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=-2.569/127.837
=-2.01%

During the past 10 years, Concord Drugs's highest Pretax Margin was 8.36%. The lowest was 0.89%. And the median was 1.83%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Concord Drugs Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Concord Drugs's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Concord Drugs (BOM:538965) Business Description

Traded in Other Exchanges
N/A
Address
3-11-451, L B Nagar, Hayatnagar Mandal, Hyderabad, TG, IND, 500074
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers. Geographically, it operates only in India.

Concord Drugs (BOM:538965) Headlines

No Headlines